PLYMOUTH, Minn.–(BUSINESS WIRE). for $4.97 million supporting development of the SX600. The scope of work supported by this grant award includes non-clinical toxicity testing of SX600, as well as manufacturing process development and scale-up activities. Together, these activities will position SX600 for future phase 3 clinical trials.
Emily Meyering, vice president of research and development, stated, “More than one in three Americans suffers from back pain each year, resulting in suffering and significant expense. Low back pain is of major concern to the US military population, with an overall incidence of 40.5 per 1,000 person-years among active-duty personnel, with Army soldiers at greatest risk. SpineThera is committed to bringing a safe and effective drug to market and the incredible support from the Department of Defense will keep the great product development momentum for SX600 as we look to the future to expand production and support later stage clinical trials. This $5 million Technology/Therapeutic Development Award is the latest example of the Department of Defense’s continued commitment to investing in technology to meet the current and future healthcare needs of our society.”
In addition to previous grants and non-dilutive funding from the National Institutes of Health, the U.S. Department of Defense, the State of Minnesota, AusIndustry and other sources, this latest award from the Department of Defense brings total grant and non-dilutive funding to over $18.5 million. USD to support the advancement of SpineTheras SX600 for epidural injection for the treatment of lumbosacral radiculopathy.
About the scholarship award
The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administration agency for procurement. This work is supported by the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under award no. W81XWH-21-1-0425 supported. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. When conducting research on animals, researchers comply with United States law and Department of Agriculture regulations.
SpineThera is a clinical-stage pharmaceutical company working to improve the lives of patients by developing injectable medicines using its microsuspension platform technology. SpineThera’s microsuspension provides months of sustained release of the active pharmaceutical ingredient with excellent injectability at ultra-high concentrations. Our goal is to develop proprietary medicines that offer patients and physicians new treatment options that reduce risk, improve outcomes and manage the overall cost of care in markets with few or no approved medicines. The Company’s lead investigational drug, SX600, is a novel formulation of dexamethasone being developed for lumbar radiculopathy. SpineThera, Inc. is based in Medical Alley, Minnesota, the global epicenter of healthcare innovation and care.